319 related articles for article (PubMed ID: 12539806)
1. Therapy to reduce risk of coronary heart disease.
Rader DJ
Clin Cardiol; 2003 Jan; 26(1):2-8. PubMed ID: 12539806
[TBL] [Abstract][Full Text] [Related]
2. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
3. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
4. Management of hypercholesterolaemia in postmenopausal women.
Davidson MH; Maki KC; Karp SK; Ingram KA
Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
[TBL] [Abstract][Full Text] [Related]
5. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
Borgia MC; Medici F
Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525
[TBL] [Abstract][Full Text] [Related]
6. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
8. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Isles CG; Paterson JR
QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
[TBL] [Abstract][Full Text] [Related]
9. Aggressive lipid management for cardiovascular prevention: evidence from clinical trials.
Friday KE
Exp Biol Med (Maywood); 2003 Jul; 228(7):769-78. PubMed ID: 12876295
[TBL] [Abstract][Full Text] [Related]
10. The rationale for combination therapy.
Rosenson RS
Am J Cardiol; 2002 Nov; 90(10B):2K-7K. PubMed ID: 12467935
[TBL] [Abstract][Full Text] [Related]
11. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
12. [Statins in primary prevention of coronary heart disease].
Paulweber B
Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
[TBL] [Abstract][Full Text] [Related]
13. Rationale for aggressive lipid lowering in high-risk patients.
Cohen JD
J Am Osteopath Assoc; 2011 Apr; 111(4 Suppl 3):eS7-12. PubMed ID: 21593473
[TBL] [Abstract][Full Text] [Related]
14. Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: getting to goal.
McKenney JM
Pharmacotherapy; 2003 Sep; 23(9 Pt 2):26S-33S. PubMed ID: 14524636
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy for combined dyslipidemia.
Xydakis AM; Ballantyne CM
Am J Cardiol; 2002 Nov; 90(10B):21K-29K. PubMed ID: 12467937
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of low HDL-cholesterol levels in the reduction of cardiovascular risk].
Stokić E; Marinkov J
Med Pregl; 2007; 60(3-4):145-50. PubMed ID: 17853726
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM
Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
[TBL] [Abstract][Full Text] [Related]
18. New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines.
Brewer HB
Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III19-24. PubMed ID: 12708635
[TBL] [Abstract][Full Text] [Related]
19. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
20. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
